Ametinib Mesilate

甲磺酸阿美替尼

Report date: 2026/03/16 20:01:47
NME

Base Information

Drug NameAmetinib Mesilate
Drug Alias NameAumolertinib甲磺酸奥美替尼aumolertinib阿美替尼Almonertinib Mesilate +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR 19del inhibitorsEGFR L858R inhibitors
TargetsEGFR T790MEGFR 19delEGFR L858R
Therapy Area/IndicationsBrain metastasesLiver DiseasesCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2020/03/17
Country/TerritoryUnited StatesNew ZealandUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHansoh Pharmaceutical Group Company LtdAbdul Latif Jameel HealthGuangzhou Institute Of Respiratory Health +[7] 
Inactive CompaniesShanghai Hansoh Biomedical Co Ltd
Active IndicationsBrain metastasesLiver DiseasesCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG